The global Immunohistochemistry Market is estimated to be valued at US$1,463.6 million in 2022 and is expected to exhibit a CAGR of 6.6% over the forecast period 2022-2030, according to a new report published by Coherent Market Insights. Market Overview: Immunohistochemistry (IHC) is a widely-used technique in the field of pathology and histology that uses specific antibodies to detect specific antigens in tissue samples. This technique provides important information about the presence and distribution of proteins, making it an essential tool in medical research and diagnostics. IHC plays a crucial role in diagnosing various diseases, aiding in tumor classification, determining treatment plans, and monitoring patient response to therapy. The global immunohistochemistry market is driven by the rising prevalence of chronic diseases, increasing demand for personalized medicine, advancements in cancer research, and growing applications of IHC in drug development. Market Key Trends: One of the key trends observed in the immunohistochemistry market is the growing adoption of multiplex immunohistochemistry. Multiplex IHC allows for the simultaneous detection of multiple antigens within a single tissue sample, providing more comprehensive information compared to conventional IHC techniques. This technique enables researchers and pathologists to study the spatial distribution of different proteins and understand their interplay within the tissue microenvironment. Multiplex IHC is particularly useful in cancer research, where it aids in the identification of biomarkers and the characterization of tumor heterogeneity. Furthermore, the development of automated staining systems and advanced imaging technologies has improved the efficiency and accuracy of multiplex IHC, further driving its adoption in research and diagnostic laboratories. Segment Analysis: The immunohistochemistry market can be segmented based on product, application, end user, and region. In terms of product, the antibodies segment dominates the market due to their high demand for disease diagnosis and research applications. Antibodies are widely used in immunohistochemistry for identifying specific antigens in tissues and cells. The increasing prevalence of chronic diseases and the growing need for personalized medicine are driving the demand for antibodies in immunohistochemistry. Based on application, the cancer diagnosis segment holds a significant share in the market. Immunohistochemistry plays a crucial role in cancer diagnosis by identifying specific biomarkers and proteins that can help determine the type, stage, and prognosis of cancer. The rising incidence of cancer globally and the increasing demand for accurate and precise cancer diagnosis are contributing to the dominance of this segment. In terms of end user, the diagnostic laboratories segment dominates the market. Immunohistochemistry tests are primarily performed in diagnostic laboratories for disease diagnosis and research purposes. The high demand for immunohistochemistry tests in diagnostic laboratories, coupled with the increasing number of diagnostic laboratories worldwide, is fueling the growth of this segment. Key Takeaways: The global Immunohistochemistry Market Share is expected to witness high growth, exhibiting a CAGR of 6.6% over the forecast period of 2022-2030. The market is driven by various factors, including the increasing prevalence of chronic diseases, the growing demand for personalized medicine, and the rising incidence of cancer. Regionally, North America is the fastest-growing and dominating region in the immunohistochemistry market. The presence of well-established healthcare infrastructure, advanced research facilities, and a high focus on R&D activities in North America are contributing to the growth of the market in this region. Additionally, the increasing adoption of immunohistochemistry in cancer diagnosis and the presence of key market players in North America further propel market growth. Key players operating in the immunohistochemistry market include Merck KGaA, Rockland Immunochemicals, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Bio SB, Agilent Technologies, Inc., Abcam plc., Becton, Dickinson and Company, Miltenyi Biotec, Biocare Medical, LLC, Eagle Biosciences, Inc., Bio-Techne, Diagnostic Biosystems, Inc., and BioGenex. These key players dominate the market through their extensive product portfolios, strategic collaborations, and strong distribution networks. They are focused on developing innovative solutions to meet the growing demand for immunohistochemistry tests and enhance their market presence.
Read More,
Rising geriatric population, growing prevalence of chronic diseases, increasing number of diagnostic centers, and increasing physician awareness & demand for histopathology are expected to fuel the growth of this market in the coming years.
However, rapid growth in the developing countries across APAC and Latin America and the increasing demand for personalized medicine offer significant growth opportunities in the immunohistochemistry market.The immunohistochemistry market is projected to reach USD 2.12 billion by 2021, at a CAGR of 7.3% during the forecast period.
Antibodies segment to dominate the global immunohistochemistry marketBased on products, the market is segmented into antibodies, reagents, kits, and equipment.
In 2015, the antibodies segment accounted for the largest share of the global immunohistochemistry market.
The rising adoption of high-throughput assays, such as array comparative genomic hybridization, cDNA microarray, next-generation sequencing techniques, and histological tests, have led to the rapid discovery of thousands of potential antibodies.Diagnostics segment accounted for largest share of immunohistochemistry marketImmunohistochemistry market is categorized into two application segments, namely, diagnostics and drug testing.
The global market for diagnostic applications is further segmented into infectious diseases, cancer, cardiovascular diseases, diabetes, autoimmune diseases, and nephrological diseases.
The global immunohistochemistry market size is expected to reach a value of USD 3.2 billion by 2027, expanding at a CAGR of 7.8%, according to a new report by Radiant Insights, Inc.
IHC has become a crucial technique and is widely applied in the diagnosis of several chronic diseases such as cancer, infectious diseases, and cardiovascular diseases (CVDs).
Thus, a rise in the incidence of these chronic diseases has led to an increase in the demand for IHC techniques.
According to 2018 data published by WHO, globally, cancer was one of the leading causes of mortality, and in 2018 around 9.6 million deaths were registered due to cancer.
Additionally, in June 2019, the U.S. FDA approved the expanded use of Agilent Technologies’ PD-L1 IHC 22C3 pharmDx assay for the detection of head and neck squamous cell carcinoma (HNSCC).
This product is used in patients receiving treatment with Merck and Co., Inc.’s Keytruda (Pembrolizumab).
